{"entity":{"id":"nct05576480","kind":"trial","name":"SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer","aka":["SPARC"],"tldr":"A phase 2 trial of penpulimab and cAPOX (capecitabine, oxaliplatin) in colorectal cancer, run by Ruijin Hospital, now recruiting.","summary":"SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer is a phase 2, interventional study registered as NCT05576480 by Ruijin Hospital, with a registry enrolment figure of 55 participants, started 2023-02-06 and due to reach its primary completion in 2025-10. Interventions recorded: Short-course radiotherapy; Penpulimab; CAPEOX; TME surgery. Conditions listed: Rectal Cancer; Locally Advanced. Primary outcome: Pathological complete remission rate (pCR). Colorectal eligibility wording from the registry: \"* Patients with pathologically confirmed rectal adenocarcinoma, assessed by MRI as mid-low rectal cancer (the lower border of the tumor is less than 10cm from the anal verge), clinical stage II-III (cT1-2N1-2M0 or T3-4N0-2M0) according to the 8th Edition of AJCC Cancer Staging Manual\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05576480","url":"https://clinicaltrials.gov/study/NCT05576480"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","imrt-igrt","platinum"],"targets":[],"drugs":["penpulimab","capox"],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05576480","phase":"2","setting":"Efficacy and Safety of Short-course Radiotherapy Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of Microsatellite Stable Locally Advanced Rectal Cancer: a Single-centre, Single-arm, Phase 2 Study","sponsor":"Ruijin Hospital","enrolled":55,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05576480/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"penpulimab","kind":"drug","name":"Penpulimab","route":"/drugs/penpulimab/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}